Modern Catalyst
The global pharmaceutical supply chain faces a critical inflection point. FDA drug shortages remain a persistent public health challenge, driven by manufacturing capacity constraints, raw-material bottlenecks, and regulatory complexity. Yet the CDMO sector is emerging as a structural solution. CDMOs now support 73% of FDA-approved drugs, and the global CDMO market is valued at more than $270 billion in 2026, expanding rapidly as sponsors recognize outsourcing as a hedge against supply disruption.
The shortage crisis is not new, but its urgency has intensified. COVID-19 exposed vulnerabilities—drug shortages and active-ingredient scarcity—that prompted bipartisan policy responses. Congress and the Joint Commission began addressing supply security, including recommendations to diversify away from single-source dependencies and consideration of API stockpiles for pandemic scenarios. These initiatives have accelerated CDMO adoption as a decentralized, resilient manufacturing model.
Recent commercial partnerships underscore this shift. Taysha Gene Therapies selected Catalent as its primary CDMO for TSHA-102, a gene therapy, exemplifying how sponsors now embed manufacturing partners early in development to ensure scalability and continuity. Simultaneously, 503B outsourcing facilities regulated by the FDA are producing large quantities of sterile and non-sterile compounded medications to address shortages and support clinical needs—a regulatory pathway that has gained prominence as traditional manufacturers face capacity constraints.
The 2026 landscape reflects a fundamental reorientation: CDMOs are no longer peripheral vendors but strategic infrastructure for supply-chain resilience.
Structural Impact
Vendor Selection & Fit-First Procurement
Procurement teams face a paradox: CDMO capacity is expanding, yet fit—not space—has become the primary selection criterion. Tech-transfer readiness, quality culture, analytics capability, and on-time deviation closure now outweigh raw manufacturing square footage. This shift reflects a hard-won lesson: a CDMO with excess capacity but weak quality systems or poor tech-transfer discipline amplifies shortage risk rather than mitigating it.
Sponsors evaluating CDMOs for shortage-critical products must assess:
- Tech-transfer maturity: Can the CDMO absorb your process, scale it reliably, and maintain consistency across manufacturing campaigns? Weak tech-transfer infrastructure prolongs time-to-market and introduces deviation risk.
- Quality culture and analytics: Persistent labor shortages and skills gaps in quality and manufacturing roles are cited as a significant headwind. A CDMO with robust training, retention, and real-time quality analytics is more likely to maintain supply continuity.
- Regulatory responsiveness: Regulatory partnerships, such as Facet Life Sciences' engagement with Nucleus, demonstrate how CDMOs increasingly embed regulatory expertise to navigate FDA interactions and submissions efficiently.
Capacity & Geopolitical Resilience
The CDMO market's $270 billion valuation masks uneven capacity distribution. While large CDMOs (Catalent, Lonza, Samsung Bioepis) command significant share, mid-tier and specialized CDMOs are filling niches in gene therapy, radiopharmaceuticals, and complex injectables. This fragmentation is intentional: supply-chain diversification away from single-source dependencies reduces geopolitical and operational risk.
However, capacity gains are offset by labor constraints. Persistent skills gaps in quality and manufacturing roles limit CDMO ability to ramp production quickly. A CDMO may have idle bioreactors but lack qualified operators or quality personnel to activate them. Procurement teams must therefore evaluate not just installed capacity but human-capital readiness.
Regulatory & Compliance Implications
The FDA's oversight of drug shortages has tightened. 503B outsourcing facilities are now a recognized regulatory pathway for addressing shortages, but they operate under distinct GMP standards and reporting requirements. Sponsors leveraging 503B partners must ensure compliance with FDA guidance on outsourcing facility oversight and supply-chain transparency.
Additionally, CDMO partnerships introduce new compliance vectors: tech-transfer documentation, deviation-closure timelines, and regulatory inspection readiness. A CDMO with weak deviation-closure discipline or poor regulatory history increases sponsor liability and delays supply recovery during shortage scenarios.
Strategic Blueprint
1. Embed CDMO Partnerships Early in Development
Delay in CDMO engagement is a hidden shortage driver. Sponsors should identify and qualify manufacturing partners during Phase II, not Phase III. Early engagement allows tech transfer to proceed in parallel with clinical development, reducing time-to-commercial-scale and enabling rapid response if supply disruptions occur.
The Taysha-Catalent partnership exemplifies this approach: by securing a commercial supply agreement before market approval, Taysha ensured manufacturing readiness and supply continuity from day one.
2. Prioritize Fit Over Capacity
When evaluating CDMO proposals, weight tech-transfer readiness, quality culture, and deviation-closure performance more heavily than available square footage. Request references from sponsors with similar products and manufacturing complexity. Audit the CDMO's quality metrics, training programs, and regulatory inspection history.
Ask specific questions:
- How many tech transfers has the CDMO completed in the past 24 months, and what was the average time-to-commercial-scale?
- What is the CDMO's on-time deviation-closure rate?
- How many FDA warning letters or observations has the CDMO received in the past three years?
3. Diversify Manufacturing Footprint
Avoid single-source CDMO dependencies. If your product is critical to patient care, establish secondary manufacturing at a geographically and operationally distinct CDMO. This approach is more costly upfront but provides insurance against supply disruption.
For shortage-critical products (e.g., oncology injectables, critical-care medications), consider a primary CDMO for commercial supply and a secondary CDMO for surge capacity or backup manufacturing.
4. Strengthen Regulatory & Quality Partnerships
Engage regulatory consultants early to align CDMO selection with FDA expectations. Regulatory partnerships embedded in CDMO strategy reduce submission delays and inspection risk.
Establish clear SLAs with your CDMO on:
- Deviation reporting and root-cause analysis timelines
- Regulatory submission support and timeline
- Supply-continuity protocols during equipment downtime or quality events
5. Monitor Labor & Skills Availability
Labor shortages in quality and manufacturing roles are a structural constraint on CDMO capacity. During vendor selection, assess the CDMO's training pipeline, retention rates, and succession planning for critical roles (quality assurance, manufacturing engineering, regulatory affairs).
Request data on:
- Turnover rates in quality and manufacturing functions
- Training hours per employee per year
- Percentage of roles filled by internal promotion vs. external hire
6. Leverage 503B Outsourcing for Shortage Mitigation
For products experiencing acute shortages, explore 503B outsourcing facilities as a complementary manufacturing pathway. 503B facilities are regulated by the FDA and can produce sterile and non-sterile compounded medications to address shortages. This pathway is faster than establishing new cGMP manufacturing but requires careful regulatory planning.
7. Build Supply-Chain Transparency & Predictability
Establish quarterly business reviews with your CDMO to review capacity utilization, deviation trends, and supply forecasts. Use real-time manufacturing data and analytics to identify bottlenecks early. Implement demand-planning tools that allow your CDMO to forecast raw-material needs and production schedules with accuracy.
Sources
- Taysha Signs Commercial Supply Agreement with Catalent for TSHA-102
- What Is a CDMO? The Complete 2026 Guide to Pharma
- Pharma Tariffs 2026: Supply Chain & Manufacturing Impacts
- RXinsider | Contract Manufacturing, Drug Shortage Mitigation
- Pharma Outsourcing 2026 Trends: FDA Cuts, Pricing
- Pharma Sourcing Trends for 2026
- Drug Shortages | FDA
- What Is cGMP vs GMP? Pharmaceutical Compliance Guide 2026